Bio-Rad Labs (BIO) PT Lowered to $477 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BIO Hot Sheet
Price: $380.36 +1.45%
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
RBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $477.00 (from $481.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- DigitalOcean (DOCN) PT Lowered to $100 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
